Lantheus Holdings, Inc.: all 77 studies

Page 1 of 1. Open to participants first (4), then studies with results posted, then the rest; newest registration first within each.

• Dose Optimization and Diagnostic Performance in Prostate Cancer (SPARROW [Staging Prostate Cancer With Advanced RM2 Radiotracer Oncologic Workup])RecruitingNCT07831824Phase 2/3
• Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)RecruitingNCT07357519Phase 1/2
• 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract CancerRecruitingNCT06298916Phase 1/2
• [18F]PI-2620 Phase 3 Histopathological StudyRecruitingNCT05641688Phase 3
• I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).CompletedNCT03939689Phase 2Results posted
• Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate CancerCompletedNCT03739684Phase 3Results posted
• DEF-315 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITYCompletedNCT03719612Phase 3Results posted
• DEF-314 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITYCompletedNCT03571672Phase 3Results posted
• Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate CancerCompletedNCT02981368Phase 2/3Results posted
• Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With ADCompletedNCT02681172Phase 4Results posted
• An Open-label Extension Study of PSMA ADC 2301 in mCRPCCompletedNCT02020135Phase 2Results posted
• A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)CompletedNCT01695044Phase 2Results posted
• A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to HistopathologyCompletedNCT01667536Phase 2Results posted
• A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.CompletedNCT01347710Phase 3Results posted
• Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mild Cognitive Impairment) PatientsCompletedNCT01138111Phase 1Results posted
• Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to HistopathologyCompletedNCT01020838Phase 3Results posted
• Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid.CompletedNCT00928304Phase 2Results posted
• A Study of Commercial DEFINITY® to Monitor the Effects of the Heart's Pulmonary Artery PressureCompletedNCT00918866Phase 4Results posted
• A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/ParagangliomaStatus unknownNCT00874614Phase 2Results posted
• Development of 1-Day Rest/Stress Cardiac PET Perfusion Imaging Protocol of BMS747158CompletedNCT00849108Phase 2Results posted
• Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy VolunteersCompletedNCT00750282Phase 2Results posted
• N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk NeuroblastomaCompletedNCT00659984Phase 2Results posted
• A Prospective, Phase IV, Surveillance Registry Study to Evaluate the Safety of DEFINITY® in Clinical PracticeCompletedNCT00625365Phase 4Results posted
• Safety and Efficacy Iodofiltic Acid I 123 in the Treatment of Acute Coronary SyndromeCompletedNCT00514501Phase 2Results posted
• Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/ParagangliomaCompletedNCT00458952Phase 1/2Results posted
• A Study of Stress Echocardiography in Post-Menopausal Women at Risk for Coronary DiseaseCompletedNCT00162370Phase 4Results posted
• A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki DiseaseCompletedNCT00162032Phase 3Results posted
• Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCCWithdrawnNCT07084909Phase 2/3
• Test-retest Study With [18F]FBB in Cardiac AmyloidosisCompletedNCT06790394Phase 1
• PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate CancerActive, not recruitingNCT06074510Phase 4
• Expanded Access Treatment with [Lu-177]-PNT2002 for Adult Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)Temporarily not availableNCT06033001
• An Observational Registry Assessing the Impact of PYLARIFY® (Piflufolastat F18) PET in Patients With Prostate CancerActive, not recruitingNCT05712473
• Imaging [18F]PI-2620 and [18F]Florbetaben in Military Service Members With Blast Related Mild Traumatic Brain InjuryTerminatedNCT05337774Phase 1
• Test-retest Study With [18F]PI-2620 in PSP-RS and NDCCompletedNCT05187546Phase 1
• Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL AmyloidosisCompletedNCT05184088Phase 3
• Evaluation of Imaging Characteristics of [18F]PI-2620 PET in AD and PSP Patients Using High and Low Specific ActivityCompletedNCT04715750Phase 1
• Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/ParagangliomaApproved for marketingNCT02961491
• Study to Evaluate 99mTc-MIP-1404 SPECT/CT Imaging in Men With Biopsy Proven Low-Grade Prostate CancerCompletedNCT02615067Phase 3
• PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate CancerTerminatedNCT02483884Phase 1/2
• PET Imaging of Intracranial Cancers With 18F-FSPGTerminatedNCT02370563Phase 1
• Open Label Study to Access Flurpiridaz F18 in PET MPI Verses SPECT MPIWithdrawnNCT01681524Phase 3
• 99mTc-MIP-1404 for Imaging Prostate Cancer: Phase I Clinical Study to Assess the Image Quality of a Simplified Kit Formulation Compared to a Multi-step Preparation of 99mTc-MIP-1404CompletedNCT01654874Phase 1
• A Phase 1 Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging to Histology in Men With Prostate CancerCompletedNCT01615406Phase 1
• Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging in Men With Prostate Cancer Undergoing Prostatectomy and/or Pelvic Lymph Node DissectionCompletedNCT01572701Phase 1
• Extended Study of Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate CancerCompletedNCT01414296Phase 1
• Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate CancerCompletedNCT01414283Phase 1
• Retrospective Safety Study to Compare Mortality in Intensive Care Unite (ICU) Patients Undergoing Echocardiography With or Without DEFINITY®CompletedNCT01299649
• PET/CT (Positron Emission Tomography / Computed Tomography) Investigations With BAY86-9596 (18F) (300 MBq) Following Single Intravenous Administration in Patients With Cancer or Inflammations.CompletedNCT01297088Phase 1
• PET/CT (Positron Emission Tomography/Computed Tomography) Imaging for Safety and Tolerability and Diagnostic Performance of BAY1075553 in Patients With Prostate Cancer and Healthy VolunteersCompletedNCT01287845Phase 1
• A Pilot Study of 123I-MIP-1072 SPECT/CT Imaging With Optional Compact Gamma Camera Probe Imaging in Men With Prostate Cancer Undergoing ProstatectomyWithdrawnNCT01279785
• A Study of 99mTc-MIP-1404 and 99mTc-MIP-1405 in Patients With Metastatic Prostate Adenocarcinoma and Healthy VolunteersCompletedNCT01261754Phase 1
• PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-7548 in Patients With Prostate Cancer and Healthy VolunteersCompletedNCT01205321Phase 1
• Exploration of Tumor Accumulation of BAY94-9392 in Patients With CancerCompletedNCT01186601Phase 1
• Evaluation of the Diagnostic Potential of BAY1006578 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of BAY1006578 in Healthy VolunteersCompletedNCT01153607Phase 1
• Prospective Evaluation of the Incidence of NSF in Patients With Kidney Disease Undergoing MRCompletedNCT01135316
• Radiation Dosimetry, Metabolism, Pharmacokinetics, Safety and Tolerability and PET Imaging With BAY94-9392 in Healthy Volunteers and Patients With Cancer or InflammationCompletedNCT01103310Phase 1
• PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability in Healthy Volunteers and Safety, Tolerability and Diagnostic Performance of BAY86-9596 in Patients With Non-small Cell Lung Cancer, Breast Cancer, Head and Neck Cancer and Patients With InflammationsCompletedNCT01089998Phase 1
• Trial to Determine Imaging Parameters of LMI1195 in Heart Failure Patients at Low and High Risk of Defibrillator FiringWithdrawnNCT01085175Phase 2
• A Long-term Follow-up Study to Evaluate the Predictive Value of BMS747158 in Patients Suspected of Coronary Artery Disease (CAD)WithdrawnNCT01085162
• A Phase I Pilot Study Comparing 123I MIP 1072 Versus 111In Capromab Pendetide in Subjects With Metastatic Prostate CancerCompletedNCT00992745Phase 1
• Efficacy and Safety of Ultratrace™ Iobenguane I 131 in NeuroblastomaWithdrawnNCT00992173Phase 2
• Study of [3H] BMS747158 in Healthy Male SubjectsCompletedNCT00930631Phase 1
• Content Validation of Quality of Life and Symptom Questionnaires for Pheochromocytoma and ParagangliomaTerminatedNCT00911729
• A Phase 1 Trial to Determine Dosimetry, Biodistribution and Safety of LMI 1195-101 in Healthy Subjects and Patients With Heart FailureCompletedNCT00891241Phase 1
• Phase I Safety and Dosimetry Study in Patients With Confirmed Metastatic MelanomaTerminatedNCT00747825Phase 1
• Study to Evaluate the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of Two Prostate Cancer Imaging AgentsCompletedNCT00712829Phase 1
• A Phase I Study in Healthy Volunteers to Assess Dosimetry and Safety Following Injection of BMS747158 at StressCompletedNCT00707538Phase 1
• A Phase I Study in Healthy Volunteers to Assess Safety of BMS747158CompletedNCT00707499Phase 1
• Study to Evaluate the Efficacy and Safety of 90Y-SMT487 in Subjects With Symptomatic Malignant Carcinoid TumorsWithdrawnNCT00696930Phase 2
• DMP115 in Patients With an Ejection Fraction Between 25%-40% to Evaluate the Use of Contrast Echocardiography to Assess Heart FunctionCompletedNCT00401687Phase 4
• ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic CarcinoidCompletedNCT00339131Phase 1
• Post-PCI:Cardiac Imaging in Patients With Diabetes to Detect Coronary Artery Blockages Previously Opened by AngioplastyCompletedNCT00162357Phase 4
• A Study of Stress Heart Imaging in Patients With Diabetes at Risk for Coronary Disease.CompletedNCT00162344Phase 4
• CARDIOLITE-413: A Study for Patients Who Had a PCI for an Acute MICompletedNCT00162331Phase 4
• A Phase II Study of DMP 115 to Assess Focal Liver LesionsCompletedNCT00162058Phase 2
• A Trial to Determine Radiation Exposure to Organs and Assess the Safety of CARDIOLITE® in Pediatric SubjectsCompletedNCT00162045Phase 1/2
• Safety and Efficacy of PRO 542 in the Treatment of HIV-Infected PatientsCompletedNCT00055185Phase 2

← Lantheus Holdings, Inc. overview and focus areas